跳至主要内容
临床试验/TCTR20190702004
TCTR20190702004招募中2 期

Correlation of Body Composition Measured by Bioelectrical Impedance Analysis and Hematologic Adverse Events in Early-stage Breast Cancer Patients Receiving Chemotherapy

Siriraj Research Fund0 个研究点目标入组 150 人开始时间: 2019年7月2日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 0 N/A (No limit)(—)
性别
Female

入选标准

  • 1. Newly diagnosed with stage I, II or III breast cancer
  • 2. Planned to receive (neo)adjuvant chemotherapy consisting of one of the following regimens: cyclophosphamide/doxorubicin (AC), docetaxel/ cyclophosphamide (TC), AC followed by paclitaxel or docetaxel, 5FU/epirubicin/cyclophosphamide (FEC) followed by docetaxel
  • 3. Signed informed consent

排除标准

  • 1. Patients with automated implantable cardioverter-defibrillator (AICD), permanent pacemaker or other metallic device
  • 2. Patients known to have pleural effusion, ascites or generalized edema

研究者

发起方
Siriraj Research Fund

相似试验